Morin, K. A.
Marsh, T. N.
Eshakakogan, C.
Eibl, J. K.
Spence, M.
Gauthier, G.
Walker, J. D.
Sayers, Dean
Ozawanimke, Alan
Bissaillion, Brent
Marsh, D. C.
Article History
Received: 28 February 2022
Accepted: 31 July 2022
First Online: 16 August 2022
Declarations
:
: The study received approval from Laurentian University’s Ethics Board in May 2017 approval no. 6010991. All methods were performed in accordance with the relevant guidelines and regulations. All participants in the prospective arm of the study provided informed consent prior to enrollment. Consent was not required for the retrospective arm and all data was de-identified.
: Not applicable.
: Dr. David Marsh maintains the following roles: Chief Medical Director at CATC (Canadian Addiction Treatment Center), opioid agonist therapy provider. Dr. Marsh has no ownership stake in the CATC as a stipendiary employee. We do not foresee any conflict of interest as data will be made freely available to the public and the CATC, and the Universities have no ability to prevent publication and dissemination of knowledge. The authors have no conflicts declared.